Skip to main content

Advertisement

Table 2 Optimization of ARVs in the three countries of Latin America, 2012-2013

From: Progress and challenges in implementing HIV care and treatment policies in Latin America following the treatment 2.0 initiative

INDICATOR Year El Salvador Venezuela Bolivia Mean
Number of first-line ART regimens in use 2012 11 14 9 11
2013 12 4 6 7
Percentage of patients in the preferred first-line ART regimens recommended by WHO (TDF + 3TC (or FTC) + EFV) 2012 85 % 39 % 98 % 74 %
2013 92 % 43 % 99 % 78 %
Percentage of patients in the preferred first-line ART regimens recommended by WHO (TDF + 3TC [or FTC] + EFV) 2012 9 % 63 % 37 % 36 %
2013 20 % 43 % 66 % 43 %
Percentage of patients in first-line ART regimens including obsolete antiretrovirals (ddl, d4T, IDV, NFV) 2012 13 % 0 % 1 % 5 %
2013 2 % 0 % 0 % 1 %
Number of second-line ART regimens in use 2012 8 % 18 % 8 % 11 %
2013 10 % 4 % 7 % 7 %
Percentage of patients in second-line ART regimens recommended by WHO 2012 55 % 0 % 74 % 43 %
2013 64 % 50 % 83 % 65 %
Percentage of patients in second-line ART regimens including obsolete ARVs 2012 35 % 1 % 19 % 18 %
2013 20 % 0 % 8 % 9 %
  1. TDF tenofovir dispoproxil fumarate, 3TC lamivudine, FTC emtricitabine, EFV efavirenz, ddl didanosine, d4T Stavudine, IDV indinavir, NFV nelfinavir, WHO World Health Organization, ARVs antiretrovirals